Evidence map›Paper›PMID 25270069›Full record

ArticleJournal of the American Society of Nephrology : JASN2015

Specific macrophage subtypes influence the progression of rhabdomyolysis-induced kidney injury.

Julie Belliere, Audrey Casemayou, Laure Ducasse, Alexia Zakaroff-Girard, Frédéric Martins, Jason S Iacovoni, Céline Guilbeau-Frugier, Bénédicte Buffin-Meyer, Bernard Pipy, Dominique Chauveau and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 153 citations in OpenAlex.

  1. Article
  2. Cytochrome bBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. The Link between Alcohol Consumption and Kidney Injury.The American journal of pathology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The novel potential therapeutic target PSMP/MSMP promotes acute kidney injury via CCR2.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  19. Rodent models of AKI and AKI-CKD transition: an update in 2024.American journal of physiology. Renal physiology · 2024
    Review
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Julie BelliereInstitut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France; Université de Toulouse III Paul Sabatier, Toulouse, France; Department of Nephrology and Organ Transplantation, Centre Hospitalier Universitaire Rangueil, Toulouse, France;
Audrey CasemayouInstitut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France; Université de Toulouse III Paul Sabatier, Toulouse, France;
Laure DucasseInstitut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France; Université de Toulouse III Paul Sabatier, Toulouse, France;
Alexia Zakaroff-GirardCytometry and Cell-sorting Platform, INSERM/Unité Mixte de Recherche U1048, Toulouse, France;
Frédéric MartinsGenome and Transcriptome Platform, Toulouse Genopole INSERM/Unité Mixte de Recherche U1048, University Paul Sabatier, Toulouse, France;
Jason S IacovoniBioinformatic Platform, INSERM/Unité Mixte de Recherche U1048, University Paul Sabatier, Toulouse, France;
Céline Guilbeau-FrugierUniversité de Toulouse III Paul Sabatier, Toulouse, France; Department of Pathology, Toulouse University Hospital, Rangueil, Toulouse, France; and.
Bénédicte Buffin-MeyerInstitut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France; Université de Toulouse III Paul Sabatier, Toulouse, France;
Bernard PipyUnité Mixte de Recherche 152, Macrophages Polarization and Nuclear Receptors, Toulouse, France.
Dominique ChauveauInstitut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France; Université de Toulouse III Paul Sabatier, Toulouse, France; Department of Nephrology and Organ Transplantation, Centre Hospitalier Universitaire Rangueil, Toulouse, France;
Joost P SchanstraInstitut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France; Université de Toulouse III Paul Sabatier, Toulouse, France; jean-loup.bascands@inserm.fr joost-peter.schanstra@inserm.fr.
Jean-Loup BascandsInstitut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France; Université de Toulouse III Paul Sabatier, Toulouse, France; jean-loup.bascands@inserm.fr joost-peter.schanstra@inserm.fr.
Inserm · FRUniversité Toulouse III - Paul Sabatier · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRCentre Hospitalier Universitaire de Toulouse · FRGenopole (France) · FRInstitut des Maladies Métaboliques et Cardiovasculaires · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhabdomyolysis can be life threatening if complicated by AKI. Macrophage infiltration has been observed in rat kidneys after glycerol-induced rhabdomyolysis, but the role of macrophages in rhabdomyolysis-induced AKI remains unknown. Here, in a patient diagnosed with rhabdomyolysis, we detected substantial macrophage infiltration in the kidney. In a mouse model of rhabdomyolysis-induced AKI, diverse renal macrophage phenotypes were observed depending on the stage of the disease. Two days after rhabdomyolysis, F4/80(low)CD11b(high)Ly6b(high)CD206(low) kidney macrophages were dominant, whereas by day 8, F4/80(high)CD11b(+)Ly6b(low)CD206(high) cells became the most abundant. Single-cell gene expression analyses of FACS-sorted macrophages revealed that these subpopulations were heterogeneous and that individual cells simultaneously expressed both M1 and M2 markers. Liposomal clodronate-mediated macrophage depletion significantly reduced the early infiltration of F4/80(low)CD11b(high)Ly6b(high)CD206(low) macrophages. Furthermore, transcriptionally regulated targets potentially involved in disease progression, including fibronectin, collagen III, and chemoattractants that were identified via single-cell analysis, were verified as macrophage-dependent in situ. In vitro, myoglobin treatment induced proximal tubular cells to secrete chemoattractants and macrophages to express proinflammatory markers. At day 30, liposomal clodronate-mediated macrophage depletion reduced fibrosis and improved both kidney repair and mouse survival. Seven months after rhabdomyolysis, histologic lesions were still present but were substantially reduced with prior depletion of macrophages. These results suggest an important role for macrophages in rhabdomyolysis-induced AKI progression and advocate the utility of long-term follow-up for patients with this disease.

Indexed as

Acute Kidney InjuryAnimalsCells, CulturedClodronic AcidDisease Models, AnimalDisease ProgressionFlow CytometryGlycerolHumansMacrophagesMaleMiceMyoglobinRandom AllocationRhabdomyolysisRisk FactorsClodronic AcidGlycerolMyoglobinacute renal failurechronic kidney diseasefibrosisImmunology and pathologymacrophages.rhabdomyolysis

Identifiers

PMID25270069
PMCPMC4446873
OpenAlexW2148969684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.